Generate Biomedicines (NASDAQ:GENB) Stock Price Crosses Below 200-Day Moving Average – Here’s Why

Generate Biomedicines Inc (NASDAQ:GENB)’s share price crossed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $14.14 and traded as low as $12.46. Generate Biomedicines shares last traded at $12.57, with a volume of 1,298,162 shares.

Wall Street Analyst Weigh In

Several research analysts have commented on GENB shares. HC Wainwright reissued a “buy” rating on shares of Generate Biomedicines in a research report on Friday, October 30th. Weiss Ratings upgraded Generate Biomedicines from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 25th. Finally, Wall Street Zen downgraded Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, October 17th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $26.40.

Generate Biomedicines Price Performance

The company’s 50-day simple moving average is $14.67 and its 200-day simple moving average is $14.14. The company has a market cap of $1.61 billion and a price-to-earnings ratio of -7.91.

Generate Biomedicines (NASDAQ:GENB) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The firm had revenue of $6.31 million for the quarter. Equities analysts predict that Generate Biomedicines Inc will post -2.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Generate Biomedicines

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Alps Advisors Inc. lifted its holdings in Generate Biomedicines by 31.4% in the 3rd quarter. Alps Advisors Inc. now owns 170,042 shares of the company’s stock worth $2,554,000 after buying an additional 40,636 shares in the last quarter. Summa Corp. purchased a new position in Generate Biomedicines in the 3rd quarter valued at about $250,000. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Generate Biomedicines by 103.1% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 78,531 shares of the company’s stock valued at $1,180,000 after acquiring an additional 39,866 shares in the last quarter. Magnus Financial Group LLC grew its stake in shares of Generate Biomedicines by 39.4% during the third quarter. Magnus Financial Group LLC now owns 21,750 shares of the company’s stock valued at $327,000 after acquiring an additional 6,150 shares in the last quarter. Finally, Bank Pictet & Cie Europe AG purchased a new stake in shares of Generate Biomedicines during the third quarter worth about $1,168,000.

Generate Biomedicines Company Profile

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence, machine learning and protein engineering to design novel protein-based medicines. Its platform is intended to identify and develop therapeutic proteins with desired biological properties, potentially shortening the time required to discover new drug candidates.

The company’s research activities focus on applying computational biology and laboratory experimentation to create medicines for a range of diseases, including conditions in immunology, inflammation, oncology and other areas of significant unmet medical need.